

## Another Breakthrough by Bio-Images

**Glasgow, U.K., March 6<sup>th</sup>, 2008** - Bio-Images Research Ltd. (Glasgow, U.K.), a leader and at the forefront of innovation in gamma scintigraphic imaging for early phase clinical trials, has launched the imaGIT™ capsule to accelerate the drug development process. Detailed knowledge of the boundaries and limitations of drug absorption through the gastro-intestinal tract is crucial for effective formulation development, and this can be successfully achieved with imaGIT™.

Resulting from years of research by Casper Associates in the USA, the breakthrough imaGIT™ capsule technology is an ingestible, radio-controlled device used to evaluate regional drug absorption in humans.

Employing Bio-Images' leading non-invasive gamma scintigraphic imaging techniques, imaGIT™ is tracked through the digestive tract following oral administration and on arrival at the desired target site, release of the contained drug is triggered by an external radio signal. Blood sampling following drug release at distant sites in the intestine allows assessment of bioavailability, the results of which assist pharmaceutical companies rationalise their formulation development strategies.

Professor Howard Stevens, Chairman, commented

*"This opportunity to collaborate with Casper Associates and utilise the imaGIT™ technology represents a major expansion of Bio-Images' early clinical capabilities. We are now able to offer our clients access to detailed knowledge of the absorption profile of their drugs throughout the gastro-intestinal tract which will permit more rational decision processes and result in accelerated drug development programmes."*

***Pushing knowledge boundaries, breaking through barriers,  
innovating in partnership with our customers.***

imaGIT™ capsules are supplied under licence from Casper Associates.